Evolus partners with IBSA to launch Profhilo in the U.S.
Evolus entered a deal with IBSA to license Profhilo, a leading European skin quality injectable. This allows the company to expand its portfolio into the fast-growing U.S. aesthetic market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day